Spike seen in prices of several Rx pain drugs

Share this article:

Dozens of prescription painkillers are up to 15 percent more costly since last year's withdrawal of Vioxx, according to a report from Consumers Union.
The Consumer Reports Best Buy Drugs report says price increases were seen among 36 pain drugs, along with growth in prescribing volume among NSAIDs (nonsteroidal anti-inflammatory drugs). Among them, prices for prescription strength Motrin, from Johnson & Johnson's McNeil-PPC, climbed 13.3 percent and Boehringer Ingelheim's Mobic, marketed in the U.S. by Abbott, jumped 10.6 percent.
Based on data from NDCHealth, the report also says 17 drugs dropped in price, and 10 remained flat.OTC medicines were not included. Merck pulled Vioxx in September after studies linked the COX-2 drug to heart problems.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.